Cartesian Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $38.9M | $26.0M | $110.8M | $85.1M | $16.6M | $6.7M | $903.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $58.0M | $45.1M | $71.3M | $72.4M | $68.7M | $54.5M | $42.7M | $47.7M |
| SG&A Expense | $31.5M | $30.1M | $40.5M | $23.9M | $20.9M | $18.9M | $16.4M | $18.2M |
| Operating Income | $-143.4M | $-43.9M | $-86.4M | $14.5M | $-4.6M | $-56.8M | $-52.5M | $-65.0M |
| Operating Margin | -5,127.1% | -112.8% | -332.3% | 13.1% | -5.4% | -342.4% | -785.6% | -7,200.7% |
| Interest Expense | — | $0 | $2.8M | $3.0M | $2.8M | $1.6M | $1.5M | $1.5M |
| Pretax Income | $-139.5M | $-77.1M | $-238.7M | $34.8M | $-9.7M | $-68.9M | $-55.4M | — |
| Income Tax Expense | $-9.2M | $287.0K | $-19.0M | $-609.0K | $16.0M | $0 | $0 | — |
| Net Income | $-130.3M | $-77.4M | $-219.7M | $35.4M | $-25.7M | $-68.9M | $-55.4M | $-65.3M |
| Net Margin | -4,658.6% | -199.0% | -844.9% | 31.9% | -30.2% | -415.0% | -829.0% | -7,235.4% |
| EPS (Basic) | $-5.02 | $-4.48 | $-16.59 | $0.08 | $-0.07 | $-0.23 | $-0.20 | $-0.49 |
| EPS (Diluted) | $-5.02 | $-4.49 | $-16.59 | $0.03 | $-0.07 | $-0.23 | $-0.20 | $-0.49 |
| Shares Outstanding (Basic) | 26.0M | 17.3M | 15.5M | 434.3M | 343.0M | 303.6M | 273.3M | 134.8M |
| Shares Outstanding (Diluted) | 26.0M | 17.4M | 15.5M | 437.6M | 343.0M | 303.6M | 273.3M | 134.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |